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Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is a non-invasive treatment approach for symptomatic uterine
ﬁbroids. One imaging characteristic considered in selecting patients who may beneﬁt from MRgFUS of their uterine ﬁbroids is
the signal intensity of the ﬁbroid compared with surrounding myometrium on T2-weighted MR images. Previous reports suggest
that hyper-intense ﬁbroids are less amenable to MRgFUS compared with iso- or hypo-intense ﬁbroids. In this case study, we
utilized contrast-enhanced dynamic MR imaging to further characterize the vascularity of a hyper-intense ﬁbroid. Based on the
results of dynamic T1-weighted contrast-enhanced images, we assumed that the hyper-intense appearance resulted from high
ﬂuid content rather than high vascularity and predicted that the ﬁbroid would respond to MRgFUS. The patient underwent the
MRgFUS without complication and reported signiﬁcant decrease in ﬁbroid symptoms at 3 and 12 months post-treatment. This
casesuggeststhatpre-treatmentdynamiccontrast-enhancedimagingusedinconjunctionwithT2-weightedimagingmayimprove
the criteria for selecting uterine ﬁbroids amenable to treatment with MRgFUS, potentially leading to improved patient outcomes.
1.Introduction
Uterine ﬁbroids are the most common tumors of the female
reproductive tract. Fibroids have been identiﬁed clinically in
at least 25% of women [1], and pathological analyses suggest
that the prevalence of ﬁbroids may be as high as 77% [2].
Although most ﬁbroids are asymptomatic, approximately
25%areassociatedwithsymptomsthatcanhaveasigniﬁcant
impact on patient’s quality of life, including prolonged
or excessive menstrual bleeding, pelvic pain or bulkiness,
dyspareunia, increased urinary frequency, and infertility [3].
Several options, each with varying degrees of inva-
siveness, are available for treatment of symptomatic uter-
ine ﬁbroids. These include among others, hysterectomy,
myomectomy (abdominal or laparoscopic), uterine artery
embolization, MR-guided Focused Ultrasound (MRgFUS),
and hormonal therapy [4], which also is sometimes provided
as an adjuvant to other therapies. Each of the treatments
has its own beneﬁts and disadvantages. For example, the
beneﬁt of hysterectomy is that the removal of the uterus
is 100% eﬀective in alleviating ﬁbroid-related symptoms
[5]. However, the procedure is invasive, requires general or
epidural anesthesia, and typically involves several weeks of
postoperative recovery time during which patients may be
limited from engaging in daily activities, including work.
MRgFUS is a non-invasive treatment for uterine ﬁbroids.
It utilizes precisely focused ultrasound waves to generate
and maintain high temperatures within the targeted ﬁbroid,
resulting in protein denaturation and coagulative necrosis
[3]. MRgFUS is integrated with magnetic resonance imaging
visualization to plan and guide treatment and to monitor
treatment outcomes in real time. This allows precise thermal2 Obstetrics and Gynecology International
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Figure 1: Patient screening MR images. (a) Axial T2-weighted image showing a heterogeneous ﬁbroid, hyper intense relative to the uterine
wall. (b) Contrast enhanced Axial T1-weighted screening MR image, showing enhancement of the ﬁbroid.
ablation of the treated ﬁbroid while preserving surrounding
normal structures.
While clinical studies demonstrate that MRgFUS is a
safe and eﬀective treatment for symptomatic uterine ﬁbroids
[6–8], not all patients are considered to be equally suitable
candidates for the procedure [9]. Potential candidates are
screened with pelvic MRI to determine if they meet patient
selection guidelines. Factors considered for MRgFUS patient
selection include the imaging characteristics and location of
the ﬁbroid within the pelvis, the number and size of ﬁbroids,
presence of structures obstructing the energy beam pathway,
andthevicinityoftheﬁbroidrelativetovulnerablestructures
[10].
One imaging characteristic considered in the patient
selection process is the ﬁbroid’s capacity to absorb heat,
as the eﬀects of MRgFUS result from the thermal ablation
of the ﬁbroid tissue. This is often assessed based on the
signalintensityoftheﬁbroidcomparedwiththesurrounding
myometrium on T2-weighted MR images (T2WIs). Previous
reports suggest that the average nonperfused volume (NPV),
as measured by posttreatment contrast-enhanced image,
obtained with MRgFUS in the treatment of hyper-intense
ﬁbroids, is lower than that achieved in iso- or hypointense
ﬁbroids [9, 11].
The following case report demonstrates successful treat-
mentofaﬁbroidthatishyper-intenseonT2WIsandsuggests
thatcontrast-enhanceddynamicMRimagingmaybeusedto
select a subpopulation of uterine ﬁbroid patients suitable for
MRgFUS despite hyper-intense results on T2WIs.
2.CaseReport
A 47-year old premenopausal Asian female, with BMI of 20,
was referred to our clinic by her gynecologist due to severe
menorrhagia. Her Symptom Severity Score (on the 0 to 100
Scale of the UFS-QoL questionnaire [12]) was 56 points.
This scale refers to patients with 21 points or more as symp-
tomatic patients. The patient was referred for MRI screening
to evaluate her suitability for the MRgFUS treatment. MRI
showed a single intramural ﬁbroid of 560cc. Intensity of
the ﬁbroid relative to the uterine wall was hyperintense on
T2WIs, and its texture was very heterogeneous (Figure 1).
To evaluate the ﬁbroid’s viability more fully, and as
part of our screening routine for MRgFUS, T1-weighted
MR images (T1WIs) with contrast were acquired. The
contrast agent used was Optimark (Covidien Imaging Solu-
tions, Missouri, U.S.). Dynamic T1-weighted gradient echo
sagittal images were acquired every 15 seconds from the
moment of injection until 180 seconds after the injection
(TR 4.81ms, TE 2.3ms, matrix 256×115, thickness 3mm,
spacing 0.6mm, FOV 30cm) (Figure 2). T1-weighted axial
fat-saturation images were taken 240 seconds after the
injection (TR 594ms, TE 11ms, matrix 256×144, thickness
5mm, spacing 1mm, FOV 30cm) (Figure 1). The images
show low enhancement in the ﬁbroid during the 120 seconds
after the injection, despite high enhancement on the 240-
second delayed scan. Based on the delayed enhancement, we
assumed that the hyper-intense appearance of this ﬁbroid
resulted from the high ﬂuid content rather than the high
vascularity, and we decided to recommend MRgFUS to the
patient.
After consulting with the patient about the potential
beneﬁts and risks involved in treating her speciﬁc ﬁbroid,
she chose to undergo MRgFUS, knowing that results might
be less than satisfactory due to the hyper-intense appearance
of her ﬁbroid. Treatment was performed using the ExAblate
2000 system (InSightec, Haifa, Israel) and SIGNA HDx MRI
(GE Healthcare, Milwaukee, U.S.). T2WIs were acquired
for treatment planning. The procedure required 128 focal
ablations (sonications) with average energy of 3300Joules.
Treatment duration was 3.5 hours from ﬁrst to last soni-
cation. Average temperature achieved was 75
◦C. Contrast-
enhanced T1WIs were acquired posttreatment, showing that
335cc (60%) of the ﬁbroid was nonenhancing (Figure 3).
The treatment was concluded without complications.
During her followup phone call the next day, she reported
returning to work and feeling well with no adverse events.
The patient provided a similar report in a phone call 7
days posttreatment. At the 3-month followup, the patient’s
symptoms signiﬁcantly improved, and her SSS score was
reduced to 28 points. At that time, the patient returned
for MR imaging, which showed 38% ﬁbroid shrinkage. At
1-year followup, which included a clinical visit to evaluate
patient’s symptoms, her SSS was reduced to 13 points, which
is considered as nonsymptomatic.Obstetrics and Gynecology International 3
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Figure 2: Contrast-enhanced sagittal T1-weighted screening MR dynamic images acquired at 30, 60, and 90 seconds post contrast injection
(from left to right). Fibroid shows lower enhancement than the myometrium in the ﬁrst 2 minutes postinjection.
Figure 3: Contrast-enhanced axial T1-weighted MR image after
treatment, showing nonperfused volume of 60%.
3. Discussion
In MRgFUS for symptomatic uterine ﬁbroid, the non-
perfused volume (NPV) of uterine ﬁbroids has been found
to correlate with treatment-related symptom relief, and to
be inversely related with the need for repeated treatment
(either MRgFUS or other therapeutic modalities) [8]. The
success and durability of MRgFUS in relieving symptoms
of uterine ﬁbroids depend on appropriate selection of
those patients in whom higher posttreatment NPV can be
obtained. Therefore, patient eligibility is an important factor
in achieving high NPV and signiﬁcant symptom relief [10].
Based on previous experience, MRgFUS treatment of
hyperintense ﬁbroids usually results in relatively poor NPVs,
and subsequent treatment failures [3]. The hyper-intensity
of these ﬁbroids on T2WIs is assumed to result either from
high concentrations of ﬂuids or from high vascularity. We
assume that either scenario makes it diﬃcult to achieve
temperatures suﬃcient for thermal ablation of ﬁbroid tissue,
which are critical to the eﬃcacy of MRgFUS. In case of
high concentrations of ﬂuids, the energy absorption by the
tissue is low, resulting in low temperatures in the focus. In
case of high vascularity the blood ﬂow disperses the heat
from the treated region. Consequently, the potential for low
NPV on post-treatment imaging, subsequent insuﬃciency of
symptom relief, and overall treatment failure in this patient
were considered.
This case report shows that hyper-intense ﬁbroids can
be successfully treated with MRgFUS, however, the ﬁbroids
should be subcategorized based on their potential for suc-
cessful treatment. T2WIs contribute to important patient-
selection information regarding the location and structure
of the ﬁbroid(s) and coexisting pathologies. T1WIs with
contrast examine the viability of the ﬁbroid and, when
performed dynamically, provide additional information on
the rate of ﬁbroid enhancement. Delayed enhancement
may indicate that the ﬁbroid has low vascularity and will
absorb suﬃcient ultrasound energy to result in successful
MRgFUS, even if the ﬁbroid appears hyper-intense on the
T2WIs.
We suggest that dynamic contrast enhancement imaging,
in addition to ﬁbroid intensity in T2WI, may provide impor-
tant information whether or not a ﬁbroid is suitable for
MRgFUS. Although in this case report, other factors could
have contributed to the treatment success, we assume that
the dynamic contrast imaging during screening helped in
patient selection. Additional studies are needed to verify this
theory and establish a correlation between the pretreatment
dynamic contrast enhancement imaging characteristics of a
given ﬁbroid and patient outcomes following MRgFUS.
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